image credit: Pixabay

First neuromodulation device for heart failure gains FDA approval

August 30, 2019

The device, Barostim Neo, is designed to activate the body’s natural blood flow regulation to treat these conditions, and can be adjusted to meet each patient’s needs. It gained approval through the premarket (PMA) pathway, and has already received a CE mark for the same indications.

A new application for neuromodulation

Due to high costs and surgical risks, the neuromodulation market has previously focused on chronic pain and neurological disorders.